Surrozen (SRZN) Common Equity (2020 - 2026)
Surrozen (SRZN) recorded quarterly Common Equity of -$278.1 million in Q1 2026, down 48.14% quarter-over-quarter from -$187.8 million in Q4 2025, and down 5002.13% on a YoY basis from $5.7 million in Q1 2025.
Surrozen (SRZN) Common Equity (2020 - 2026) Analysis & Trends
Surrozen's Common Equity history runs 7 years deep, the most recent figure standing at -$278.1 million for Q1 2026.
- In Q1 2026, Common Equity fell 5002.13% year-over-year to -$278.1 million; the TTM figure through Mar 2026 stood at -$278.1 million (down 5002.13% YoY), while the FY2025 annual figure was -$187.8 million, down 778.21% from the prior year.
- Common Equity was -$278.1 million for Q1 2026 at Surrozen, down from -$187.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $102.7 million in Q1 2022 to a low of -$278.1 million in Q1 2026.
- Historically, Common Equity has averaged $7.7 million across 5 years, with a median of $37.9 million in 2023.
- The sharpest annual moves came in 2025 and 2026: Common Equity surged 677.2% in 2025, then slumped 5002.13% in 2026.
- A 5-year view of Common Equity shows it stood at $76.0 million in 2022, then tumbled by 50.09% to $37.9 million in 2023, then slumped by 156.36% to -$21.4 million in 2024, then tumbled by 778.21% to -$187.8 million in 2025, then tumbled by 48.14% to -$278.1 million in 2026.
- The last three Common Equity figures came in at -$278.1 million (Q1 2026), -$187.8 million (Q4 2025), and -$23.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 14.38 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 13.21 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | -278.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -278.15 Mn |
| Dec 31, 2025 | -187.76 Mn |
| Sep 30, 2025 | -23.52 Mn |
| Jun 30, 2025 | 47.11 Mn |
| Mar 31, 2025 | 5.67 Mn |
| Dec 31, 2024 | -21.38 Mn |
| Sep 30, 2024 | 5.67 Mn |
| Jun 30, 2024 | 6.06 Mn |
| Mar 31, 2024 | 30.14 Mn |
| Dec 31, 2023 | 37.94 Mn |
| Sep 30, 2023 | 45.53 Mn |
| Jun 30, 2023 | 55.06 Mn |
| Mar 31, 2023 | 63.04 Mn |
| Dec 31, 2022 | 76.00 Mn |
| Sep 30, 2022 | 77.49 Mn |
| Jun 30, 2022 | 89.70 Mn |
| Mar 31, 2022 | 102.66 Mn |
| Dec 31, 2021 | 109.70 Mn |
| Sep 30, 2021 | 123.73 Mn |
| Jun 30, 2021 | 22.82 Mn |